Indian firms fear US generic user fee would raise the cost of business
This article was originally published in SRA
Executive Summary
The Indian generic industry has reacted with measured optimism to the recent US Food and Drug Administration-industry agreement on generic drug user fees1, with some experts arguing that there are currently more questions than answers on the proposed fee-based programme's workability.